Efflux transporter P-glycoprotein (P-gp) at the blood-brain barrier (BBB) restricts substrate
compounds from entering the brain and may thus contribute to pharmacoresistance …

The expression of membrane drug transport systems in the central nervous system plays an
important role in the brain disposition and efficacy of many pharmacological agents used in …

Disruption of the blood–brain barrier (BBB) is a characteristic finding in common
neurological disorders. Human data suggest BBB disruption may underlie cerebral …

Introduction P‐glycoprotein (P‐gp) is an efflux transporter responsible for the transport of
various drugs across the blood‐brain barrier (BBB). Loss of P‐gp function with age may be …

Purpose: The multidrug transporter P‐glycoprotein (P‐gp) is expressed at high levels in a
variety of tissues such as the endothelial cells of the blood–brain barrier (BBB) capillaries …

Until recently, the blood‐brain barrier was viewed as a static lipid membrane barrier.
Physical attributes of the cerebral endothelial cells such as the presence of tight junctions …

The blood–brain barrier is part of the neurovascular unit and serves as a functional and
anatomical barrier between the blood and the extracellular space. It controls the flow of …

Positron emission tomography was used to measure global and local blood flow in 11
patients with hemiparkinsonism (before and after an acute oral dose of L-dopa) and in 26 …

Increased expression of drug efflux transporters at the blood-brain barrier accompanies
epileptic seizures and complicates therapy with antiepileptic drugs. This study is concerned …

Permeability of the blood-brain barrier (BBB) is one of the factors determining the
bioavailability of therapeutic drugs. The BBB only allows entry of lipophilic compounds with …